(Q37960638)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22115405%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Modeling and predicting drug pharmacokinetics in patients with renal impairment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22115405%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22115405%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Karen Rowland Yeo

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22115405%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Masoud Jamei

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22115405%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Amin Rostami-Hodjegan

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22115405%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

language of work or name

English

0 references

publication date

1 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22115405%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Clinical Pharmacology

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22115405%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22115405%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

261-274

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22115405%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22115405%20AND%20SRC:MED&resulttype=core&format=json

Drug dosing in chronic kidney disease

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Drug metabolism in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

The effect of chronic renal failure on hepatic drug metabolism and drug disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Effects of renal diseases on the regulation and expression of renal and hepatic drug-metabolizing enzymes: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Hepatic drug metabolism and transport in patients with kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Effects of renal failure on drug transport and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Emerging evidence of the impact of kidney disease on drug metabolism and transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Drug development perspective on pharmacokinetic studies of new drugs in patients with renal impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Simulation and prediction of in vivo drug metabolism in human populations from in vitro data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Clinical epidemiology of cardiovascular disease in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

The burden of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Prevalence of chronic kidney disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

The epidemiology of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Drug dosing in renal insufficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Principles of drug administration in renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Assessing kidney function--measured and estimated glomerular filtration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Measured and estimated GFR in healthy potential kidney donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Absorption potential: estimating the fraction absorbed for orally administered compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

A compartmental absorption and transit model for estimating oral drug absorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Predicting the impact of physiological and biochemical processes on oral drug bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Population-based mechanistic prediction of oral drug absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Clinical pharmacokinetics of antibiotics in patients with impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recogn

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Prediction of the volumes of distribution of basic drugs in humans based on data from animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Iron status and hemoglobin level in chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Factors influencing drug protein binding in patients with end stage renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Drug protein binding in chronic renal failure: Evaluation of nine drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Protein binding predictions in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Drug interactions with antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Influence of renal failure on the hepatic clearance of bufuralol in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

The human intestinal cytochrome P450 "pie".

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Prediction of intestinal first-pass drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Downregulation of intestinal cytochrome p450 in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

The physiological function of drug-transporting P-glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Effect of chronic renal failure on the expression and function of rat intestinal P-glycoprotein in drug excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Measurement of the renal clearance of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Effect of plasma protein binding on renal clearance of drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Genetic variants of the organic cation transporter 2 influence the disposition of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Pharmacokinetic-pharmacogenetic modelling in the detection of polymorphisms in xenobiotic metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Backtracking booze with Bayes--the retrospective interpretation of blood alcohol data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

The effect of environmental factors on the pharmacokinetic behaviour of organic solvent vapours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Dose of midazolam should be reduced during diltiazem and verapamil treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

N-monodesmethyldiltiazem is the predominant metabolite of diltiazem in the plasma of young and elderly hypertensives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on th

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Insulinotropic meglitinide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Utilization of estimated physicochemical properties as an integrated part of predicting hepatic clearance in the early drug-discovery stage: Impact of plasma and microsomal binding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Maraviroc: in vitro assessment of drug-drug interaction potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Model-based drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Pharmacokinetics of flutamide in patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FECP.10.143

21 January 2018

Identifiers

DOI

10.1586/ECP.10.143

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22115405%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference